Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go. Pfizer ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024. The ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...